|
|||||
|
|
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities |
|
| Authors: | Desikan R Barlogie B Sawyer J Ayers D Tricot G Badros A Zangari M Munshi N C Anaissie E Spoon D Siegel D Jagannath S Vesole D Epstein J Shaughnessy J Fassas A Lim S Roberson P Crowley J |
| Affiliation: | Myeloma and Transplantation Research Center and Division of Biometry, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. |
| Abstract: | High-dose therapy (HDT) has increased complete remission (CR) rates and survival in multiple myeloma (MM). We now report on continuous CR (CCR) and associated prognostic factors in 1000 consecutive patients receiving melphalan-based tandem HDT. Five-year CCR was 52% among 112 CR patients without chromosome 13 (triangle up13) abnormalities and with beta-2-microglobulin |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |
| 点击此处可从《Blood》浏览原始摘要信息 | |
| 点击此处可从《Blood》下载全文 | |